Poster Background
Developing effective therapies for glioblastoma (GBM) relies on robust preclinical animal models that enable detailed investigation of tumor biology, discovery of therapeutic targets, and evaluation of new treatment strategies. Mouse models, in particular, remain central to GBM research due to their genetic flexibility and translational relevance. In this study, we developed a spatial phenotyping workflow to characterize the immune and neural microenvironment of the mouse brain. Using the PhenoCode™ Discovery Mouse Neurobiology Panel in combination with custom markers, we optimized an imaging strategy and analysis approach using mouse GBM tissues. This iterative process enabled comprehensive profiling of key proteins in FFPE mouse brain samples. The resulting workflow demonstrates that the PhenoCode™ Discovery Mouse Neurobiology Panel provides an off-the-shelf,scalable solution for spatial characterization of diverse cell populations within the mouse brain microenvironment.
Explore our ready-to-use Mouse Neurobiology PhenoCode Discovery Panel or Human Neurobiology PhenoCode Discovery Panel for high-plex spatial phenotyping of neurons, glial populations, and immune cells at single-cell resolution in mouse or human tissue, respectively.
Related Posts
Oncology
Development of a Spatial Metabolic Map of Immunotherapy Sensitive and Resistant Cutaneous Skin Carcinoma
Poster Background Ultrahigh-Plex Single-cell Spatial Phenotyping has revealed valuable insights into the tumor immune microenvironment (TiME) for biomarker discovery and stratification of clinical responses. Metabolic reprogramming is a key hallmark…
Spatial Immunometabolic Profiling of Non-Small Cell Lung Cancer Reveals Distinct Immune Exclusion Patterns and Functional Niches
Analytical validation of a multiplex immunofluorescence 7-Biomarker Immunoprint® assay on the Akoya PhenoImager HT platform for stage I/II Melanoma
Neurology
Neurodegenerative biomarkers in different chambers of the eye relative to plasma: an agreement validation study
Alzheimer’s Research and Therapy | August 26, 2024 Sampani K, Ness S, Tuz-Zahra F, Aytan N, Spurlock EE, Alluri S, Chen X, Siegel NH, Alosco ML, Xia W, Tripodis Y,…
Neurology
Clinical validation of the LucentAD p-Tau 217 as a lab developed test (LDT) for clinical use
Poster The intersection of new therapeutic options for Alzheimer’s disease (AD), the emergence of accurate blood-based tests for AD, and the anticipated health system log jam for confirmatory diagnostic testing…
Neurology
Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice
Alzheimer’s & Dementia | August 3, 2024 Verberk IMW, Jutte J, Kingma MY, Vigneswaran S, Gouda MMTEE, van Engelen MP, Alcolea D, Arranz J, Fortea J, Lleó A, Chevalier C,…
Neurology
Discovering novel plasma biomarkers for ischemic stroke: Lipidomic and metabolomic analyses in an aged mouse model
Journal of Lipid Research | August 2, 2024 Becktel DA, Frye JB, Le EH, Whitman SA, Schnellmann RG, Morrison HW, Doyle KP. J Lipid Res. 2024 https://doi.org/10.1016/j.jlr.2024.100614 Abstract Ischemic stroke…
Neurology
Primate cerebrospinal fluid CHI3L1 reflects brain TREM2 agonism
Alzheimer’s & Dementia | August 1, 2024 Schauer SP, Cho CH, Novikova G, Roth GA, Lee J, Sharma AD, Foley AR, Ng C, Shen P, Choi M, Ma TP, Phu…